Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Update on extended-release opioids in pain management.

Sloan P.

Expert Opin Drug Deliv. 2014 Feb;11(2):155-8. doi: 10.1517/17425247.2014.866090. Epub 2013 Dec 4.

PMID:
24299558
[PubMed - indexed for MEDLINE]
2.

Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic noncancer pain.

Nicholson B.

Postgrad Med. 2013 Jan;125(1):115-27. doi: 10.3810/pgm.2013.01.2627. Review.

PMID:
23391677
[PubMed - indexed for MEDLINE]
3.

Assessment of extended-release opioid analgesics for the treatment of chronic pain.

Gudin JA.

J Pain Palliat Care Pharmacother. 2013 Mar;27(1):49-61. doi: 10.3109/15360288.2012.757575. Review.

PMID:
23527669
[PubMed - indexed for MEDLINE]
4.

Recent advances in opioid prescription for chronic non-cancer pain.

Snidvongs S, Mehta V.

Postgrad Med J. 2012 Feb;88(1036):66-72. doi: 10.1136/pgmj.2010.112045. Epub 2011 Jul 1. Review.

PMID:
21725034
[PubMed - indexed for MEDLINE]
5.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
[PubMed - indexed for MEDLINE]
6.

Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.

Stanos S.

Phys Sportsmed. 2012 Nov;40(4):12-20. doi: 10.3810/psm.2012.11.1975. Review.

PMID:
23306411
[PubMed - indexed for MEDLINE]
7.

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective.

Mercadante S, Craig D, Giarratano A.

Drugs. 2012 Dec 24;72(18):2327-32. doi: 10.2165/11642230-000000000-00000. Review.

PMID:
23116252
[PubMed - indexed for MEDLINE]
8.

Extended-release opioids for the management of chronic non-malignant pain.

Sloan P, Babul N.

Expert Opin Drug Deliv. 2006 Jul;3(4):489-97. Review.

PMID:
16822224
[PubMed - indexed for MEDLINE]
9.

Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain.

Nicholson B.

Pain Pract. 2009 Jan-Feb;9(1):71-81. doi: 10.1111/j.1533-2500.2008.00232.x. Epub 2008 Oct 27. Review.

PMID:
19019047
[PubMed - indexed for MEDLINE]
10.

Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic.

Gibofsky A, Barkin RL.

Am J Ther. 2008 May-Jun;15(3):241-55. doi: 10.1097/MJT.0b013e3181727f68. Review.

PMID:
18496262
[PubMed - indexed for MEDLINE]
11.

Extended-release formulations of tramadol in the treatment of chronic pain.

Pergolizzi JV Jr, Taylor R Jr, Raffa RB.

Expert Opin Pharmacother. 2011 Aug;12(11):1757-68. doi: 10.1517/14656566.2011.576250. Epub 2011 May 24. Review.

PMID:
21609187
[PubMed - indexed for MEDLINE]
12.

Responsible prescribing of opioids for the management of chronic pain.

Nicholson B.

Drugs. 2003;63(1):17-32. Review.

PMID:
12487620
[PubMed - indexed for MEDLINE]
13.

Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.

Gudin J.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):136-43. doi: 10.3109/15360288.2012.679724.

PMID:
22764852
[PubMed - indexed for MEDLINE]
14.

The use of long-acting opioids in chronic pain management.

Vallerand AH.

Nurs Clin North Am. 2003 Sep;38(3):435-45. Review.

PMID:
14567201
[PubMed - indexed for MEDLINE]
15.

Tapentadol extended release for chronic pain patients.

Taylor R, Pergolizzi JV, Raffa RB.

Adv Ther. 2013 Jan;30(1):14-27. doi: 10.1007/s12325-013-0002-y. Epub 2013 Jan 15. Review.

PMID:
23328938
[PubMed - indexed for MEDLINE]
16.

Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?

Candiotti KA, Gitlin MC.

Curr Med Res Opin. 2010 Jul;26(7):1677-84. doi: 10.1185/03007995.2010.483941. Review.

PMID:
20465361
[PubMed - indexed for MEDLINE]
17.

Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain.

Anastassopoulos KP, Chow W, Tapia CI, Baik R, Ackerman SJ, Biondi D, Kim MS.

J Manag Care Pharm. 2012 Oct;18(8):615-26.

PMID:
23127149
[PubMed - indexed for MEDLINE]
Free Article
18.

Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.

Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH.

Clin Ther. 2013 May;35(5):659-72. doi: 10.1016/j.clinthera.2013.03.016. Epub 2013 Apr 13.

PMID:
23587608
[PubMed - indexed for MEDLINE]
19.

Efficacy of tapentadol ER for managing moderate to severe chronic pain.

Afilalo M, Morlion B.

Pain Physician. 2013 Jan;16(1):27-40. Review.

PMID:
23340531
[PubMed - indexed for MEDLINE]
Free Article
20.

Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.

Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W.

J Pain Palliat Care Pharmacother. 2010 Dec;24(4):333-48. doi: 10.3109/15360288.2010.524979. Review.

PMID:
21133741
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk